Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894472 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2HIF1ABLM | |
| Water SCHEMBL8680777 | 0.98 | SMN1; SMN2 (0.34) | SMN1; SMN2HIF1ABLM | |
| SCHEMBL19065141 | 0.82 | SMN1; SMN2 (0.32) | SMN1; SMN2HIF1A | |
| SCHEMBL9717846 | 0.82 | SMN1; SMN2 (0.32) | SMN1; SMN2HIF1A | |
| SCHEMBL19065143 | 0.82 | SMN1; SMN2 (0.32) | SMN1; SMN2HIF1A | |
| SCHEMBL26092373 | 0.81 | BLM (0.31) | SMN1; SMN2HIF1ABLM | |
| SCHEMBL59405 | 0.81 | BLM (0.47) | SMN1; SMN2HIF1ABLM | |
| SCHEMBL163221 | 0.81 | BLM (0.47) | SMN1; SMN2HIF1ABLM | |
| SCHEMBL59406 | 0.81 | BLM (0.47) | SMN1; SMN2HIF1ABLM | |
| SCHEMBL13702468 | 0.81 | BLM (0.33) | BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107205948-B | Tablets comprising a GLP-1 agonist and an enteric coating | 诺和诺德股份有限公司 | 2021-12-14 | — | — | CN | claimed |
| CN-107205948-A | Tablets comprising a GLP-1 agonist and an enteric coating | 诺和诺德股份有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-105154498-A | Semi-recombinant preparation of GLP-1 analogues | NOVO NORDISK AS | 2015-12-16 | — | — | CN | claimed |
| CN-101842109-A | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK AS | 2010-09-22 | — | — | CN | claimed |
| CN-115925994-A | Polypeptide Conjugates and Methods of Use | 北京质肽生物医药科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115925995-A | Polypeptide Conjugates and Methods of Use | 北京质肽生物医药科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114729060-B | Polypeptide conjugates and methods of use | 北京质肽生物医药科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115260313-A | Fusion proteins of GLP-1 and GDF15 and conjugates thereof | 北京质肽生物医药科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-107205948-B | Tablets comprising a GLP-1 agonist and an enteric coating | 诺和诺德股份有限公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-106008569-B9 | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-05-22 | — | — | CN | disclosed |
| CN-106008569-B | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-04-03 | — | — | CN | disclosed |
| CN-110769846-A | Solid composition for oral administration | 诺和诺德股份有限公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2013148966-A1 | TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES | AMYLIN PHARMACEUTICALS, LLC (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013009545-A1 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION WITH REDUCED IMMUNOGENICITY | AMYLIN PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| CN-102361647-A | Fgf21 derivatives with albumin binder a-b-c-d-e- and their use | NOVO NORDISK AS | 2012-02-22 | — | — | CN | disclosed |
| CN-101868476-A | Glucagon-like peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK AS | 2010-10-20 | — | — | CN | disclosed |
| CN-101842109-A | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK AS | 2010-09-22 | — | — | CN | disclosed |
| EP-2118131-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | CovX Technologies Ireland Limited (IE) | 2009-11-18 | — | — | EP | disclosed |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008081418-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | SMN1; SMN2 3888/4885HIF1A 1106/4885BLM 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.